tbuckley/cabot-search huggingface dataset:
Addiction
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Using Clinical Trial Summary Results to Establish Quality Measures—Reply
Authors: Rodney Hayward, David M. Kent
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chlorodyne Dependence
Authors: R. R. Parker, J. P. Cobb, P. H. Connell
Journal: BMJ (1974)

Eight cases of chlorodyne dependence seen in a London drug clinic are described. These cases and the results of an inquiry among pharmacies in central and south London suggest that this form of drug dependence is commoner among younger people than has been supposed and that the total number of chlorodyne-dependent people in Greater London may exceed 1,000. The prognosis for cure is poor. We recommend that the supply of chlorodyne, now available without prescription to the public, should be restricted.
Tumor Promoters and Cocarcinogens in Tobacco Carcinogenesis
Authors: D. Hoffmann, S. S. Hecht, E. L. Wynder
Journal: Environmental Health Perspectives (1983)

Cigarette smoke induces carcinoma of the larynx in Syrian golden hamsters and is active as a tumor promoter in hamsters pretreated with a low dose of a PAH, nitrosamine, or nitrosamide. These tumorigenic effects are only observed with total smoke, but not with the gas phase alone. This demonstrates that the tumorigenic agents reside primarily in the particulate phase. According to fractionation experiments, a number of four- and five-ring aromatic hydrocarbons serve as the major tumor initiators in tobacco smoke. Tumor promoters reside primarily in weakly polaric neutral subfractions and in the weakly acidic portion of the particulate matter and include certain unsaturated hydrocarbons and phenolic compounds. Cocarcinogenic activity is a characteristic feature of tobacco smoke and its particulates. Among the cocarcinogens formed during combustion are catechols and certain nontumorigenic aromatic hydrocarbons and terpenes. Nicotine may also serve as a cocarcinogen as is indicated by preliminary data. The action of tumor promoters and cocarcinogens in tobacco carcinogenesis, the precursors for tobacco smoke promoters and cocarcinogens, and methods for their reduction in smoke are discussed.
Seventh International Cancer Congress Applications and Travel Allotments
Journal: JNCI Journal of the National Cancer Institute (1957)

Seventh International Cancer Congress Applications and Travel Allotments Get access JNCI: Journal of the National Cancer Institute, Volume 19, Issue 3, September 1957, Page 465, https://doi.org/10.1093/jnci/19.3.465 Published: 01 September 1957
USE OF THE SIGMOID FLEXURE AND CECUM IN PELVIC PERITONIZATION
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Controlled trials for neonatal meningitis
Authors: C. J. Mulder
Journal: JAMA (1985)

<h3>To the Editor.—</h3> Dr McCracken and co-workers<sup>1</sup>compared two therapeutic regimens in 63 children with "neonatal" gram-negative meningitis. Fifteen of these children were older than 30 days. In group A, 60% of the cases were caused by<i>Escherichia coli</i>, and the age at onset of illness was 29 ± 19 days and in group B, only 45% of the cases were caused by<i>E coli</i>, and the age at onset of illness was only 19 ± 18 days. We demonstrated that<i>E coli</i>neonatal meningitis has a lower case-fatality rate than non-<i>E coli</i>gramnegative meningitis,<sup>2,3</sup>and that the case-fatality rate in the younger age group (0 to 6 days of age) was higher than in the older age group (7 to 27 days of age).<sup>4,5</sup> The results of McCracken et al must be interpreted in light of these facts. Furthermore, the interpretation of their results is difficult
Parallel 34: Hepatitis B: Outcomes of Approved Therapy
Journal: Hepatology (2014)

313Awith pIFN/RBV or with a DAA regimen for only 8 weeks, subjects with lower methylation levels showed a more favorable response to treatment relative to subjects with higher methylation levels.This analysis identifies a new parameter for identifying difficult-to-treat subjects, and may provide mechanistic insight into the role of IFNλ3 genetic variants in HCV treatment response.
Refinements in criteria for the determination of death: an appraisal. A report by the Task Force on Death and Dying of the Institute of Society, Ethics, and the Life Sciences
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does an Association between Pesticide Use and Subsequent Declines in Catch of Atlantic Salmon (Salmo salar) Represent a Case of Endocrine Disruption?
Authors: Wayne L. Fairchild, Erin O. Swansburg, Jacqueline T. Arsenault, Scott B. Brown
Journal: Environmental Health Perspectives (1999)

Historical aerial applications of the insecticide Matacil 1.8D provide an opportunity to look for potential effects of the endocrine disrupting compound 4-nonylphenol (4-NP) on Atlantic salmon (Salmo salar) populations. Matacil 1.8D contained the carbamate insecticide aminocarb, with 4-NP as primary solvent. Between 1975 and 1985 Matacil 1.8D was applied to forests in Atlantic Canada to control damage from the spruce budworm (Choristoneura fumiferana). After spraying, estimated concentrations of 4-NP in water fell within a range in which estrogenic effects might be anticipated. The spraying coincided with final stages of smolt development in salmon. Salmon catch data were evaluated considering effects on survival of the smolt stage. There was a significant negative relationship between the returns of salmon and the proportion of tributaries sprayed within the Restigouche River drainage basin in 1977. There was also a broader event of unusually heavy salmon smolt mortality in 1977, which contains a significant relationship indicating that where Matacil 1.8D spraying occurred, the smolt mortality increased. For 16 rivers exposed to spraying between 1973 and 1990, a significant proportion (p<0.005) of the lowest salmon catches coincided with Matacil 1.8D spraying. A decline coinciding with the use of Matacil 1.8D was also apparent in blueback herring (Alosa aestivalis) catches in New Brunswick. Because similar relationships were not evident for Matacil 1.8F or fenitrothion, neither of which were formulated with 4-NP, we hypothesize that the 4-NP in Matacil 1.8D was the causal agent. Concentrations of 4-NP described here are within current ranges encountered in industrial effluents and municipal sewage outfalls.
Two Doors
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annual Report of the Board of Health and the City and Port of Phila= delphia for the year 1895.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0120 IGA Autoantigens – A Link Between the GUT and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Independent Clinical Trials
Authors: Z. Konthur, U. Nonhoff, M.M. Wiemkes, J. Detert, T. Braun, J. Hollidt, G.-R. Burmester, K. Skriner
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> So far no mechanism for non response to biologicals targeting TNFa has been described, despite one third of rheumatoid arthritis patients treated are Non-Responder. A link to the gut microbiota and its ability to drive an autoimmune disease (Immunity. 2010, 32(6):815–27) can be made via segmented filamentous bacteria (SFB) that cooperate to generate potent IgA and Th17 cell responses (Immunity. 2014, 40(4):608–20). <h3>Objectives</h3> We investigated the differences in seroreactivity of patients responding and not responding to anti-TNF therapies prior therapy and identified a diagnostically applicable set of IgA autoantigens to identify non response. <h3>Methods</h3> Baseline sera form PREDICT trial treated with Enbrel and patients treated with Humira in the HIT HARD trial (Ann Rheum Dis. 2013, 72(6):844–509) as well as 66 baseline sera from Charité in addition treated with Cimzia and Remicade were investigated on different autoantigens, which were previously identified by protein array screening. The five identified autoantigens (RAB11B, PPP2R1A, KPNB1, COG4, FTFT1) were developed into the pre.mark-TNF ELISA kit by DRDx GmbH. <h3>Results</h3> Biologicals-naïve sera from patients diagnosed with RA according to ACR classification criteria, which were initiated on therapy with TNFalpha inhibitors, were analysed with the pre. mark-TNF ELISA kit. In total, analyses of 203 patients were carried out, of which 162 were clearly defined as Responder and 41 clearly defined as Non-Responder after 6 month treatment. 81% of Non-Responder could be clearly identified with the pre. mark-TNF Test. Currently the assay shows a specificity of 94% within this group of 162 Responder. In detail, 80 baseline serum samples from the PREDICT trial (Enbrel) and 57 samples of the HIT HARD (Humira) trial were analysed. In HIT HARD – an early intervention study – all 3 Non-Responder were identified and the specificity of the assay was 98%. In the PREDICT study, Non-Responder were identified with a sensitivity of 69% and a specificity of 93%. Further analysis revealed that the amount of IgA producing B-cells in the synovia differs significantly between patients, while no difference is seen in IgG producing B-cells. Moreover of local TNF-alpha is produced from IgA B-cells in RA synovial tissue and TNFalpha producing macrophages via IgA stimulation. <h3>Conclusions</h3> These data suggest that non-response to anti-TNFalpha biologicals might be predicted based on frequency and magnitude of autoantibodies to specific IgA autoantigens. SFB can stimulate IgA production and Th17-cell responses and specific local IgA-producing B-cells might be decisive. <h3>Disclosure of Interest</h3> None declared
OCULAR NEURASTHENIA.
Authors: HIRAM WOODS
Journal: JAMA (1907)

For several years I have been greatly interested in studying the relations of remote nervous conditions to eye work or ocular disease. My attention was, I believe, first centered on the subject by a number of cases of chorioiditis in young persons where syphilis, rheumatism and tuberculosis were excluded.<sup>1</sup>Other physical troubles were present, which I have since come to believe causes of uveal inflammation. Five years ago a young girl who suffered from asthenopia, which I could not relieve, and who had certain accommodative symptoms which one would unhesitatingly attribute to hysteria, developed a small area of exudative chorioiditis. In short, there had apparently been a series of symptoms of an "irritative" type, if I may use the term, ending in objective inflammation. This child recovered from the chorioiditis, but certain intestinal derangements persisted; and with them an inability to do much eye work. Of course the latter
Progress Toward Poliomyelitis Eradication — Afghanistan, January 2018–May 2019
Authors: Maureen Martinez, Hemant Shukla, Joanna Nikulin, Chukwuma Mbaeyi, Jaume Jorba, Derek Ehrhardt
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Since October 2016, Afghanistan and Pakistan have been the only countries with reported cases of wild poliovirus type 1 (WPV1) (1). In Afghanistan, although the number of cases had declined during 2013-2016, the polio eradication program experienced challenges during 2017-2019. This report describes polio eradication activities and progress in Afghanistan during January 2018-May 2019 and updates previous reports (2,3). During May-December 2018, insurgent groups (antigovernment elements) banned house-to-house vaccination in most southern and southeastern provinces, leaving approximately 1 million children inaccessible to oral poliovirus vaccine (OPV) administration. During January-April 2019, vaccination targeting children at designated community sites (site-to-site vaccination) was permitted; however, at the end of April 2019, vaccination campaigns were banned nationally. During 2018, a total of 21 WPV1 cases were reported in Afghanistan, compared with 14 during 2017. During January-May 2019, 10 WPV1 cases were reported (as of May 31), compared with eight during January-May 2018. Sewage sample-testing takes place at 20 sites in the highest-risk areas for poliovirus circulation; 17 have detected WPV1 since January 2017, primarily in the southern and eastern provinces. Continued discussion with antigovernment elements to resume house-to-house campaigns is important to achieving polio eradication in Afghanistan. To increase community support for vaccination, collaboration among humanitarian service agencies to address other urgent health and basic needs is critical.
Control and Management of Insect Populations by Chemosterilants
Authors: Alexej B. Borkovec
Journal: Environmental Health Perspectives (1976)

Chemosterilants, i.e., chemical compounds that interfere with the reproduction potential of sexually reproducing organisms, can be used in three new approaches to insect control. In the sterile-insect release technique, the principal problem is to develop compounds and methods for their application that would not result in introducing harmful residues into the environment. Because of the unusual and often unique circumstances connected with releasing large numbers of sterilized insects, the residue problem and its cost-benefit aspects must be examined individually for each intended control or eradication program. In the direct application technique, chemosterilants must meet the same efficiency and safety standards required from approved insecticides. Combined insecticidal and sterilizing activity is characteristic for some compounds now being investigated. In the genetic technique, chemosterilants may be used for inducing heritable changes in the insect's genome under laboratory conditions, and such procedures would not present any residue problems. Only the first two chemosterilant techniques are approaching practical application, and their safety aspects require detailed evaluation and assessment.
Serum Transaminase Activity (SGOT and SGPT) in Liver Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE MENACE OF MORBIDITY
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal